» Articles » PMID: 28399655

Cyclic GMP-AMP As an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA

Overview
Publisher Annual Reviews
Specialty Biochemistry
Date 2017 Apr 13
PMID 28399655
Citations 124
Authors
Affiliations
Soon will be listed here.
Abstract

The innate immune system functions as the first line of defense against invading bacteria and viruses. In this context, the cGAS/STING [cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase/STING] signaling axis perceives the nonself DNA associated with bacterial and viral infections, as well as the leakage of self DNA by cellular dysfunction and stresses, to elicit the host's immune responses. In this pathway, the noncanonical cyclic dinucleotide 2',3'-cyclic GMP-AMP (2',3'-cGAMP) functions as a second messenger for signal transduction: 2',3'-cGAMP is produced by the enzyme cGAS upon its recognition of double-stranded DNA, and then the 2',3'-cGAMP is recognized by the receptor STING to induce the phosphorylation of downstream factors, including TBK1 (TANK binding kinase 1) and IRF3 (interferon regulatory factor 3). Numerous crystal structures of the components of this cGAS/STING signaling axis have been reported and these clarify the structural basis for their signal transduction mechanisms. In this review, we summarize recent progress made in the structural dissection of this signaling pathway and indicate possible directions of forthcoming research.

Citing Articles

Targeting the PRMT1-cGAS-STING signaling pathway to enhance the anti-tumor therapeutic efficacy.

Huang D, Rezaeian A, Wang J, Qi Y, Chen H, Inuzuka H J Cancer Biol. 2025; 5(2):44-60.

PMID: 40018367 PMC: 11867627. DOI: 10.46439/cancerbiology.5.064.


Pyrithione zinc alters mismatch repair to trigger tumor immunogenicity.

Zhang H, Wu J, Cui L, Wang T, Jin H, Guo H Oncogene. 2025; .

PMID: 39814851 DOI: 10.1038/s41388-024-03272-1.


Novel Modifications and Delivery Modes of Cyclic Dinucleotides for STING Activation in Cancer Treatment.

Lu Y, Li Z, Zhu X, Zeng Q, Liu S, Guan W Int J Nanomedicine. 2025; 20():181-197.

PMID: 39802380 PMC: 11721825. DOI: 10.2147/IJN.S503780.


Mitochondrial diseases: from molecular mechanisms to therapeutic advances.

Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X Signal Transduct Target Ther. 2025; 10(1):9.

PMID: 39788934 PMC: 11724432. DOI: 10.1038/s41392-024-02044-3.


The antiviral activity of myricetin against pseudorabies virus through regulation of the type I interferon signaling pathway.

Song Y, Zhao X, Chen Y, Yu X, Su T, Wang J J Virol. 2024; 99(1):e0156724.

PMID: 39601590 PMC: 11784099. DOI: 10.1128/jvi.01567-24.